Based on recent statements, the U.S. Department of Justice seems poised to provide
much needed guidance regarding the manner and extent of corporate cooperation credit
in False Claims Act cases. Examination of newly available data, however, demonstrates
that more wide-ranging, structural changes are necessary: The data raises substantial
questions not only about the credit given for cooperation, but about what the DOJ
values
in resolving FCA cases and whether there is appropriate consistency for cases handled
by
U.S. attorneys' offices across the country.
As originally published in Compliance Week - "Top Mind of Tomorow: 'Hope to pay it
forward'" - Editor’s note: Seton Hall Law student Hannah Levine was named CW’s first-ever
Top Mind of Tomorrow, and with it earned an invitation to attend our recently concluded
annual conference at Washington, D.C.’s Mayflower Hotel. In her own words, Hannah
describes her experience at the event. Read More >>
On October 25, Seton Hall Law and Mayer Brown LLP were pleased to present the annual
“Hot Topics in Life Sciences Law” Symposium. With over 100 industry professionals
in attendance, the symposium explored emerging issues and legal trends impacting the
life sciences industry. Read More >>
Professors John Jacobi, Jacob T. Elberg, Tara Adams Ragone, and Laura Hoffman represented
Seton Hall Law at the American Society of Law, Medicine & Ethics Annual Health Law
Professors Conference. The icing on the cake for Seton Hall Law was the bestowal of
an award for lifetime achievement on Professor Jacobi and the selection of Professor
Elberg as a promising new Health Law Scholar. Read More >>
The US Department of Justice has launched an investigation into the sales and marketing
of a drug approved three years ago to help treat Parkinson's patients suffering from
debilitating psychosis. Former DOJ attorney and Seton Hall Law Professor Jacob T.
Elberg weighs in.
From TIME: An Oklahoma judge ordered Johnson & Johnson to pay $572 million for its
role in the opioid crisis in a historic ruling on Monday, marking the first time an
opioid manufacturer has been deemed responsible in court and made to pay damages.
It could have implications for the slew of lawsuits filed against opioid manufacturers
and distributors throughout the country." Read Professor John Jacobi's comments on the issue >>
After a three-year hiatus, Seton Hall Law is proud to publish three new articles in
the online student journal, Health Law Outlook. This student-run publication of Seton
Hall Law’s Health Law Forum, is an institutional eRepository showcasing the work of
students under one umbrella. Students explore current and emerging issues in scholarly
articles, through which they contribute to the rapidly evolving discourse in health
law and policy. Three recent graduates contributed to Volume 10, Issue 1. Read More >>
A Seton Hall University School of Law professor and director of the Health & Pharmceutical
Law & Policy Program, Jacobi's reach extends beyond the classroom and into the hub
of state health care policy. There are several people who have cited his work, or
sought his expertise, on health care issues, most importantly on public health and mental health - the latter which is taking center stage in the
state.
Innovation & Health Law
Jessica Gottlieb Empestan '02 and Daniel Gottlieb '09, siblings and colleagues
Jessi Empestan (pictured, left), regulatory counsel in the Law Department of Johnson & Johnson, and her brother,
Dan Gottlieb (pictured, center), an associate with Epstein, Becker & Green, P.C. in Washington, D.C., represent the
first time that two siblings graduated from Seton Hall Law with a concentration in
Health Law. This program, founded by Dean Kathleen Boozang (pictured, right) is consistently ranked among the top 10 in U.S. News & World Reports. Read the full story.